On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.

• Bharat Electronics Shares Fall Over 2% Despite Rs 770 Crore Radar Deal
• Key Factors Behind Today’s Market Decline
• Stocks in Focus: Seamec, Bharat Electronics, and Others 
• Stocks Under F&O Ban: Ambuja Cements, and Others 
• SEAMEC Signs Rs 519.4 Crore Contract With HAL; Shares Trade Flat

Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).

The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.